微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 66.44% | 3.41% | 0.88% | 36/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 65.86% | 4.31% | 2.03% | 42/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 64.55% | -6.67% | -0.02% | 40/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 64.56% | -7.66% | 0.49% | 42/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 64.25% | -10.18% | 1.75% | 40/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 63.14% | -8.5% | -8.71% | 41/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 69.16% | 34.34% | -1.09% | 35/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 69.92% | 50.32% | -2.24% | 31/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 71.53% | 66.06% | 3.65% | 32/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 69.01% | 88.87% | 34.04% | 31/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 51.48% | 37.71% | 10.68% | 73/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 46.51% | 20.4% | 7.99% | 87/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 43.07% | 9.69% | 17.88% | 96/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 36.54% | -6.68% | -2.27% | 106/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 37.38% | -6.32% | -3.23% | 106/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 38.63% | -4.08% | -1.62% | 101/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 39.27% | -2.97% | 0.29% | 102/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 39.15% | -0.39% | -1.88% | 95/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 39.91% | 19.3% | -0.92% | 105/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 40.27% | 20.14% | -0.49% | 91/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 40.47% | 26.74% | 2.96% | 97/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 39.31% | 2% | 17.51% | 86/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 33.45% | 6.71% | -0.22% | 121/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 33.52% | 2% | 4.98% | 102/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 31.93% | 4.78% | 1.87% | 113/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 31.35% | 4.91% | 2.85% | 116/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-06-30 | 30.48% | 2% | 2% | 99/157 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | 29.88% | 35.3% | 35.3% | 115/157 | -211.97% | 微芯生物 | 96.09% | 行业排名> |
| 2017-12-31 | 22.08% | 20.47% | 20.47% | 115/157 | 52.55% | 微芯生物 | 96.11% | 行业排名> |
| 2016-12-31 | 18.33% | 0.32% | 0.32% | 109/157 | 48.46% | 微芯生物 | 95.5% | 行业排名> |